Statin Therapy Decreases Serum Levels of High-Sensitivity C-Reactive Protein and Tumor Necrosis Factor-α in HIV-Infected Patients Treated With Ritonavir-Boosted Protease Inhibitors

Calza, Leonardo; Trapani, Filippo; Bartoletti, Michele; Manfredi, Roberto; Colangeli, Vincenzo; Borderi, Marco; Grossi, G.; Motta, Roberto; Viale, Pierluigi

doi:10.1310/hct1303-153

Cited by 48 publications

(28 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, statins have been shown to decrease markers of immune activation among HIV-infected patients not on ART[88] and inflammatory markers in treated HIV-infected patients. [89] Data on the effect of statins on clinical outcomes (apart from lipid-lowering effects) among HIV-infected patients are scarce, and no study has specifically investigated the association of statin use with cardiovascular event rates. All-cause mortality was decreased by 67% with statin use in patients from the Johns Hopkins HIV clinical cohort who achieved virologic suppression after ART initiation.…”

Section: Clinical Strategies: Moving Towards Hiv-specific Interventionsmentioning

confidence: 99%

Cardiovascular Disease and HIV Infection

2013

View full text Add to dashboard Cite

The emergence of chronic disease complications in controlled HIV disease has changed the landscape of HIV clinical care. HIV infection confers an increased cardiovascular disease risk which is thought to be due to a complex interplay of mechanistic factors. While traditional cardiovascular risk factors likely play a role, recent evidence suggests that HIV-associated inflammation and immune activation are important mediators of cardiovascular risk. It is unclear whether established preventative interventions for the general population are applicable to HIV-infected patients, and the need to translate mechanistic knowledge into HIV-specific clinical interventions represents an important priority. Developing strategies to prevent cardiovascular disease in HIV-infected individuals calls for a multidisciplinary approach and represents an opportunity to exert a major public health impact in an at-risk population.

show abstract

Section: Clinical Strategies: Moving Towards Hiv-specific Interventionsmentioning

confidence: 99%

Cardiovascular Disease and HIV Infection

2013

View full text Add to dashboard Cite

show abstract

“…Statins have shown antiviral activity against influenza virus due to their anti-inflammatory activities (81). All three statins, namely, rosuvastatin, atorvastatin, and pravastatin, could lead to a significant reduction in serum levels of hsCRP and tumor necrosis factor alpha (TNF-␣) in HIV patients (82). Treatment with rosuvastatin caused significantly greater decreases in total cholesterol and low-density lipoprotein cholesterol than subjects on atorvastatin or pravastatin.…”

Section: Repurposing Existing Drugs For Treatment Of Ebola Patientsmentioning

confidence: 99%

Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks

Haque

Hober

Blondiaux³

2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

c Ebola virus can cause severe hemorrhagic disease with high fatality rates. Currently, no specific therapeutic agent or vaccine has been approved for treatment and prevention of Ebola virus infection of humans. Although the number of Ebola cases has fallen in the last few weeks, multiple outbreaks of Ebola virus infection and the likelihood of future exposure highlight the need for development and rapid evaluation of pre-and postexposure treatments. Here, we briefly review the existing and future options for anti-Ebola therapy, based on the data coming from rare clinical reports, studies on animals, and results from in vitro models. We also project the mechanistic hypotheses of several potential drugs against Ebola virus, including small-molecule-based drugs, which are under development and being tested in animal models or in vitro using various cell types. Our paper discusses strategies toward identifying and testing anti-Ebola virus properties of known and medically approved drugs, especially those that can limit the pathological inflammatory response in Ebola patients and thereby provide protection from mortality. We underline the importance of developing combinational therapy for better treatment outcomes for Ebola patients.

show abstract

“…Both elevated hs-CRP and HIV infection were found to be independent risk factors for risk of acute myocardial infarction in adults 58 and increased hs-CRP concentrations have been associated with increased CIMT in HIV-infected adults 59 and children 60 . Statin use resulted in decreased hs-CRP in HIV-infected adults in some studies 61,62 but not others 63 . Although both hs-CRP and IL-6 concentrations appeared to decrease in this study after initiation of atorvastatin, the variability was high for both analytes.…”

Section: Discussionmentioning

confidence: 91%

Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia

Melvin

Montepiedra

Aaron

et al. 2017

Pediatric Infectious Disease Journal

View full text Add to dashboard Cite

Background HIV-infected children receiving antiretroviral therapy (ART) have increased prevalence of hyperlipidemia and risk factors for cardiovascular disease. No studies have investigated the efficacy and safety of statins in this population. Methods HIV-infected youth aged 10 - < 24 years on stable ART with low-density lipoprotein-cholesterol (LDL-C) ≥130 mg/dL for ≥ 6 months initiated atorvastatin 10mg once daily. Atorvastatin was increased to 20mg if LDL-C efficacy criteria (LDL-C < 110 mg/dL or decreased ≥30% from baseline) were not met at week 4. Primary outcomes were safety and efficacy. Results Twenty-eight youth initiated atorvastatin; 7 were 10 - 15 years and 21 were 15 - 24 years. Mean baseline LDL-C was 161mg/dL (sd 19mg/dL). Efficacy criteria were met at week 4 by 17/27(63%). Atorvastatin was increased to 20mg in 10 participants. Mean LDL-C decreased from baseline by 30% (90% CI: 26%, 35%) at week 4, 28% (90% CI: 23%, 33%) at week 24, and 26% (90% CI: 20%, 33%) at week 48. LDL-C was less than 110 mg/dL in 44% at week 4, 42% at week 12, and 46% at weeks 24 and 48.Total cholesterol (TC), non-high-density lipoprotein (non-HDL)-C and apolipoprotein B (ApoB) decreased significantly, but IL-6 and high-sensitivity C-reactive protein did not. Two participants in the younger age group discontinued study for toxicities possibly related to atorvastatin. Conclusions Atorvastatin lowered TC, LDL-C, non-HDL-C and ApoB in HIV-infected youth with ART-associated hyperlipidemia. Atorvastatin could be considered for HIV-infected children with hyperlipidemia, but safety monitoring is important particularly in younger children.

show abstract

Statin Therapy Decreases Serum Levels of High-Sensitivity C-Reactive Protein and Tumor Necrosis Factor-α in HIV-Infected Patients Treated With Ritonavir-Boosted Protease Inhibitors

Abstract: Our findings suggest that rosuvastatin has a significantly greater lipid-lowering effect than atorvastatin or pravastatin, but all 3 statins exert a similar effect in lowering markers of inflammation as hsCRP and TNF-α.

Cited by 48 publications

References 36 publications

Cardiovascular Disease and HIV Infection

Cardiovascular Disease and HIV Infection

Addressing Therapeutic Options for Ebola Virus Infection in Current and Future Outbreaks

Safety and Efficacy of Atorvastatin in Human Immunodeficiency Virus-infected Children, Adolescents and Young Adults With Hyperlipidemia

Contact Info

Product

Resources

About